Get the Daily Brief
Latest Biotech News
Kymera patents STAT6 inhibitors: wide therapeutic claims
Kymera Therapeutics filed and disclosed patents covering new STAT6 inhibitors claimed for cancer, inflammatory and autoimmune diseases, cardiovascular disorders, neurodegeneration and viral...
mRNA engineering upgrades allogeneic MSCs — DC-25 emerges
Researchers reported an mRNA‑engineering approach that enhanced mesenchymal stem cells to create an allogeneic cell therapy candidate named DC‑25. The study describes mRNA modifications that...
CRISPR test spots BK/JC after kidney transplant — rapid viral surveillance
A team led by Liu, Y., Xu JS, and Cao L. developed a CRISPR‑based assay to detect BK virus and JC virus infections in kidney transplant recipients. The assay targets viral nucleic acids with...
Senescent cell vaccine reduces solid tumors: study shows immune clearance
Ichim et al. published preclinical data on a senescent cell immunization approach that primes the immune system to target senescent cells within solid tumors. The Journal of Translational Medicine...
VCs urge maturity-first strategy — how biotechs cross the 'valley of death'
Industry investors at the LSX Investival Showcase EU told biotech founders to prioritize technical validation, platform maturity and alternative financing to survive the funding gap between seed...
FDA’s ‘plausible mechanism’ pathway: experts split
The FDA-authored 'plausible mechanism pathway' proposal for expedited approval of bespoke therapies has provoked both praise and criticism from regulators, clinicians and developers. The...
Valley of death: investors push biotechs to prove maturity
Investors at LSX Investival told early-stage biotech founders that venture capital alone is no longer sufficient to cross the 'valley of death.' Private equity and alternative financiers are...
mRNA retools MSCs: DC-25 aims for scalable cell therapy
Researchers have engineered mesenchymal stromal cells (MSCs) with mRNA to enhance their immunotherapeutic properties and created an allogeneic cell product termed DC-25. The study demonstrates...
Off-the-shelf mRNA vaccines: new approach targets liver cancer
Researchers published preclinical data for off‑the‑shelf mRNA vaccine formulations targeting hepatocellular carcinoma (HCC), demonstrating antigen-specific immune activation in tumor models. The...
Kedrion scores EU orphan tag for aceruloplasminemia therapy
Kedrion SpA announced that the European Medicines Agency (EMA) granted orphan drug designation to its investigational plasma‑derived treatment for congenital aceruloplasminemia. The designation...
Preclinical oncology surge: TEAD inhibitor and GD2 ADC show potency
Two preclinical programs reported strong efficacy in aggressive tumor models: Vivace Therapeutics’ VT‑3989, a TEAD inhibitor, suppressed growth of NF2‑deficient meningioma models; and M‑3554, an...
Pancreatic T‑cell engager shows traction – gene‑editing delivery follows
HCW Biologics presented preclinical efficacy for HCW11‑018, a T‑cell engager demonstrating anti‑tumor activity in pancreatic cancer models, while a separate translational study outlined...
WGS from FFPE: clinical‑grade genomes from archived tissue
A new method enables robust whole‑genome sequencing (WGS) from formalin‑fixed, paraffin‑embedded (FFPE) specimens, overcoming longstanding technical barriers that limited genomic analysis of...
CAR‑macrophages cut liver fibrosis… NEK7 links mitochondrial control
Two liver‑fibrosis studies reported complementary advances: engineered CAR‑macrophage therapy reduced fibrosis in mouse models, offering a cell‑based anti‑fibrotic approach; separately,...
Boehringer reveals cGAS inhibitors; Kymera patents STAT6 tools
Two discovery disclosures landed this week: Boehringer Ingelheim reported novel cyclic GMP‑AMP synthase (cGAS) inhibitors aimed at autoinflammatory interferonopathies and fibrotic/metabolic lung...
FDA’s plausible mechanism pathway: Streamlined route for bespoke rare-disease treatments
US regulatory officials published a 'plausible mechanism pathway' in The New England Journal of Medicine proposing an expedited approval route for bespoke therapies for ultra-rare diseases. The...
NMPA clears JMT-206: CSPC moves obesity candidate to clinic
China’s National Medical Products Administration granted clinical trial clearance to CSPC Pharmaceutical Group for JMT-206, an investigational agent for weight management in people with obesity or...
SK Biopharma licenses WT‑7695: Acquires global rights to preclinical radiopharmaceutical
SK Biopharmaceuticals struck an exclusive worldwide license with the Wisconsin Alumni Research Foundation for WT‑7695, a preclinical-stage radiopharmaceutical developed with the University of...
CrisprBits nets $3M... to scale CRISPR diagnostics and R&D
Indian CRISPR diagnostics startup CrisprBits closed a US$3 million Pre‑Series A round led by Spectrum Impact, the family office of Rajendra Gogri, to expand diagnostics, gene‑editing tools and...
WGS from FFPE—New method unlocks tumor genomes for precision oncology
Researchers published a methodology enabling robust whole‑genome sequencing (WGS) from formalin‑fixed, paraffin‑embedded (FFPE) tissue, overcoming long-standing technical challenges in archival...